Muri, Jonathan; Cecchinato, Valentina; Cavalli, Andrea; Shanbhag, Akanksha A; Matkovic, Milos; Biggiogero, Maira; Maida, Pier Andrea; Toscano, Chiara; Ghovehoud, Elaheh; Danelon-Sargenti, Gabriela; Gong, Tao; Piffaretti, Pietro; Bianchini, Filippo; Crivelli, Virginia; Podešvová, Lucie; Pedotti, Mattia; Jarrossay, David; Sgrignani, Jacopo; Thelen, Sylvia; Uhr, Mario; ... (23 May 2022). Anti-chemokine antibodies after SARS-CoV-2 infection correlate with favorable disease course. (bioRxiv). Cold Spring Harbor Laboratory 10.1101/2022.05.23.493121
|
Text
nihpp-2022.05.23.493121v1.pdf - Published Version Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND). Download (6MB) | Preview |
Infection by SARS-CoV-2 leads to diverse symptoms, which can persist for months. While antiviral antibodies are protective, those targeting interferons and other immune factors are associated with adverse COVID-19 outcomes. Instead, we discovered that antibodies against specific chemokines are omnipresent after COVID-19, associated with favorable disease, and predictive of lack of long COVID symptoms at one year post infection. Anti-chemokine antibodies are present also in HIV-1 and autoimmune disorders, but they target different chemokines than those in COVID-19. Finally, monoclonal antibodies derived from COVID- 19 convalescents that bind to the chemokine N-loop impair cell migration. Given the role of chemokines in orchestrating immune cell trafficking, naturally arising anti-chemokine antibodies associated with favorable COVID-19 may be beneficial by modulating the inflammatory response and thus bear therapeutic potential.
One-Sentence Summary
Naturally arising anti-chemokine antibodies associate with favorable COVID-19 and are predictive of lack of long COVID.
Item Type: |
Working Paper |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Infectiology |
UniBE Contributor: |
Rauch, Andri |
Subjects: |
600 Technology > 610 Medicine & health |
Series: |
bioRxiv |
Publisher: |
Cold Spring Harbor Laboratory |
Language: |
English |
Submitter: |
Annelies Luginbühl |
Date Deposited: |
31 Aug 2022 09:24 |
Last Modified: |
05 Dec 2022 16:20 |
Publisher DOI: |
10.1101/2022.05.23.493121 |
PubMed ID: |
35664993 |
BORIS DOI: |
10.48350/170610 |
URI: |
https://boris.unibe.ch/id/eprint/170610 |
Actions (login required)
 |
Edit item |